News for Iovance Biotherapeutics, Inc. (IOVA)

PR NewswireNASHVILLE, Tenn., March 4, 2025 FY 2024 revenue of $228.4 million, in-line with company guidanceCommercial Cell & Gene Therapy revenue rose to $

Texas-based Interactive Strength Inc. (TRNR) is up over 30 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Release Date: February 27, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Iovance Biot

Exploring the competitive edge of Iovance Biotherapeutics Inc's innovative TIL therapies in the biopharmaceutical landscape.Assessing the challenges and potent

Iovance Biotherapeutics shares dip 18% despite strong Q4 results due to concerns over inflation, geopolitical risks, and operational challenges. Read more here.

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 3.70% and 2.26%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Iovance Biotherapeutics Inc (IOVA), a leader in developing tumor infiltrating lymphocyte (TIL) therapies, announced its financial results for the fourth quarter

The following slide deck was published by Iovance Biotherapeutics, Inc.

Significant Demand for Amtagvi® (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M in FY24, Achieving Upper End of FY24 Guidance R

**media[552835]**

**media[546990]**

Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAN CARLOS, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. ( IOVA), a biotechnology company focused on innovating, developing, and de

Overview of the Recent Transaction On December 31, 2024, PERCEPTIVE ADVISORS LLC (Trades, Portfolio) made a strategic move by acquiring 2,440,000 shares of Ante

Overview of the Recent Transaction On December 31, 2024, PERCEPTIVE ADVISORS LLC (Trades, Portfolio) made a significant move by acquiring 84,000,000 shares of T

On December 31, 2024, PERCEPTIVE ADVISORS LLC (Trades, Portfolio) executed a significant transaction involving Biodesix Inc (BDSX). The firm added 4,500,000 sha

On December 31, 2024, PERCEPTIVE ADVISORS LLC (Trades, Portfolio), a prominent investment firm, executed a significant transaction involving Contineum Therapeut

Transaction Overview On December 31, 2024, PERCEPTIVE ADVISORS LLC (Trades, Portfolio) made a significant move by acquiring 5,880,000 shares of RAPT Therapeutic